Takeda Pharmaceutical Quote - TAK

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

12.60

Bid

Offer

Volume

1,695,792

12.60 Day's Range 12.71

0.00 52 Week Range 0.00

Market Cap

154.849B

Previous Close

12.61

Open

12.62

Last Trade

12.71

Last Trade Time

Financial Volume

US$ 21,453,310

VWAP

12.6509

Average Volume (3m)

Shares Outstanding

3,137,776,702

Dividend Yield

4.99%

PE Ratio

1.07

Earnings Per Share (EPS)

45.91

Revenue

4.28T

Net Profit

144.07B

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geogr... Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Diversified

Website

www.takeda.co.jp

Headquarters

Chuo, Tokyo, Jpn

Founded

1984

Takeda Pharmaceutical Company Ltd is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker TAK. The last closing price for Takeda Pharmaceutical was US$12.61. Over the last year, Takeda Pharmaceutical shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Takeda Pharmaceutical currently has 3,137,776,702 shares in issue. The market capitalisation of Takeda Pharmaceutical is US$154.85 billion. Takeda Pharmaceutical has a price to earnings ratio (PE ratio) of 1.07.

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for Metastatic Colorectal Cancer (mCRC...

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in...

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older Canada...

武田薬品、PNS年次総会にて慢性炎症性脱髄性多発神経炎（CIDP）患者を対象としたHYQVIA®の第3相ADVANCE-CIDP3臨床試験の長期データを発表

CIDPにおける最も長期間な公開臨床試験から、HYQVIAがCIDPの安定した疾病経過を維持するための有効な長期治療の選択肢であるとする好ましい結果が得られた ADVANCE臨床プログラムが、希少な神経免疫疾患患者に...

Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (P

Les résultats positifs du plus long essai clinique sur la PIDC soutiennent HYQVIA en tant qu’option de traitement à long terme efficace pour maintenir la stabilité de la maladie en cas de PIDC...

Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung

Günstige Ergebnisse der längsten öffentlichen klinischen Studie bei CIDP unterstützen HYQVIA als wirksame Langzeit-Behandlungsoption zur Aufrechterhaltung eines stabilen Krankheitsverlaufs bei...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

SKYLINE Study in Dravet Syndrome Narrowly Missed its Primary Endpoint of Reduction in Convulsive Seizure Frequency and Showed Clinically Meaningful and Nominally Significant Effects in Multiple...

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

− Takeda to Receive Exclusive Option to License Global Rights to Olverembatinib in All Territories Outside of Mainland China, Hong Kong, Macau, Taiwan and Russia − Olverembatinib Has the...

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts

The New Expanded Partnership Will Aim to Support the Dismantling of Systemic Barriers to Equity and Help Strengthen the Health Workforce in Massachusetts The Existing Global Partnership Has...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ME1OEMelodiol Global Health Ltd	AUD 0.006 (100.00%)	34
K2FK2fly Limited	AUD 0.1825 (82.50%)	2.49M
PRXProdigy Gold NL	AUD 0.003 (50.00%)	100.11k
ARVOCArtemis Resources Limited	AUD 0.003 (50.00%)	1.05M
MTBMount Burgess Mining Nl	AUD 0.0015 (50.00%)	5.38k
BNROBulletin Resources Limited	AUD 0.001 (-66.67%)	100k
FRSOAForrestania Resources Ltd	AUD 0.006 (-57.14%)	26k
GGEOAGrand Gulf Energy Limited	AUD 0.001 (-50.00%)	2.18M
D2OOADuxton Water Limited	AUD 0.021 (-47.50%)	4.5k
CT1Constellation Technologies Limited	AUD 0.002 (-33.33%)	50.02k
REDRed 5 Limited	AUD 0.4175 (3.09%)	135.31M
BGLBellevue Gold Limited	AUD 1.835 (-1.34%)	81.32M
NICNickel Industries Ltd	AUD 0.825 (-3.23%)	62.62M
S32South32 Limited	AUD 3.74 (1.77%)	56.22M
CXOCore Lithium Ltd	AUD 0.0855 (-6.04%)	56.06M

Monksdream 3 months ago

TAK over $10

👍️0

Boing x 2 1 year ago

Just saying,

https://www.takeda.com/newsroom/newsreleases/2022/takedas-biologics-license-application-bla-for-dengue-vaccine-candidate-tak-003-granted-priority-review-by-us-food-and-drug-administration

4 months or less until an answer. Expedited review is six months or less now. It was accepted Nov 22nd.

Big if we get FDA apprvoval. ETF's in the know are sucking up shares.

Other approved drug has serious side effects vs. ours.

300M cases a year from mosquito bites.

Boing X 2

👍️0

Phosphene 4 years ago

Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade

https://www.businesswire.com/news/home/20201208005955/en/Takeda%E2%80%99s-Pipeline-Has-Potential-to-Contribute-Significantly-to-Revenue-Growth-Over-Next-Decade

👍️0

Phosphene 4 years ago

Japan's Takeda eyes new focus on vaccines after OTC asset sales - CEO

https://www.reuters.com/article/health-coronavirus-takeda-vaccines-idUSKBN27M0F7

👍️0

Phosphene 4 years ago

MIT-Takeda program launches

Research projects will harness the power of artificial intelligence to positively impact human health.

https://news.mit.edu/2020/mit-takeda-program-launches-research-ai-and-human-health-0618

👍️0

rising 6 years ago

Takeda shares tumbled as much as 9.3 percent in early trading in Tokyo on Wednesday. The Japanese company is offering the equivalent of 49 pounds ($68.55) per share, including 27.26 pounds in stock and 21.75 pounds in cash, Shire said in a statement. That’s a 60 percent premium to Shire’s closing share price on March 27, before Takeda disclosed it was interested in the US drug maker.

ADR is 3:1 - NICE!
60 percent upside
Added 36.83 US stock
Added 29.38 US cash

Not a bad deal!

👍️0

rising 6 years ago

So how does the Shire shareholder make out on this deal?

Takeda shares tumbled as much as 9.3 percent in early trading in Tokyo on Wednesday. The Japanese company is offering the equivalent of 49 pounds ($68.55) per share, including 27.26 pounds in stock and 21.75 pounds in cash, Shire said in a statement. That’s a 60 percent premium to Shire’s closing share price on March 27, before Takeda disclosed it was interested in the US drug maker.

Where is the 60percent premium to Close of March 27 2018 at shire 128.87

👍️0

trendmkr 8 years ago

Takeda article: enGene Shines with a Host of Big Name Collaborations

http://marketexclusive.com/engene-shines-with-a-host-of-big-name-collaborations/1281/

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Takeda Pharmaceutical Company Ltd (TAK)

Professional-Grade Tools, for Individual Investors.

Key stats and details

About Takeda Pharmaceutical Company Ltd

TAK Latest News

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older

武田薬品、PNS年次総会にて慢性炎症性脱髄性多発神経炎（CIDP）患者を対象としたHYQVIA®の第3相ADVANCE-CIDP3臨床試験の長期データを発表

Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (P

Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

武田薬品、PNS年次総会にて慢性炎症性脱髄性多発神経炎（CIDP）患者を対象としたHYQVIA®の第3相ADVANCE-CIDP3臨床試験の長期データを発表

Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (P

Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts

Market Movers

TAK Discussion

Your Recent History

Company

Business

Popular

Get The App

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Takeda Pharmaceutical Company Ltd (TAK) Share Price

Takeda Pharmaceutical Company Ltd (TAK)

Professional-Grade Tools, for Individual Investors.

Key stats and details

About Takeda Pharmaceutical Company Ltd

TAK Latest News

Market Movers

TAK Discussion

Your Recent History

Company

Business

Popular

Get The App

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR